Stay ahead in the Clear Aligner industry

Most DSOs treat aligner cases under a supplier's name, building someone else's brand with their own patients and chairs. Groups with real case volume are now launching branded aligner programs they own outright — keeping the margin and the patient relationship without the cost or complexity of running a factory. This post covers what ownership changes, how to pick a manufacturing partner, and why the timing matters.

Private label aligner manufacturing is growing fast. Dental groups, labs, and DSOs are building their own brands for better margins, brand equity, and control over patient experience. The model only works if the manufacturer is built to support it. Inconsistent quality, incomplete regulatory coverage, and refinement economics that damage profitability all trace back to one decision: who manufactures the product. This post breaks down what separates serious infrastructure from

Something is shifting in orthodontics. The clinicians who spent years driving volume for established aligner brands are now building their own — not as a side project, but as a deliberate decision about where the value in their work actually lives. In 2026, more than 35% of K Line's incoming inquiries come from individual orthodontists or small groups asking the same question: how do we launch our own aligner brand? That number reflects a structural shift, not a trend. Aligne

Most US dental labs cannot manufacture aligners in-house — cost, equipment, and FDA requirements put it out of reach. So a new model is emerging: partnering with certified manufacturers to offer aligners under their own brand. With the orthodontic segment growing fastest in dental lab services and DSOs reshaping pricing, labs that act in the next 12 to 18 months will retain their dentist relationships for the next decade.

Building a private label aligner brand is one thing. Running one efficiently is another. Most brands source their treatment planning and manufacturing separately. And the gap between those two steps is where cases get complicated. Each time a case moves from treatment planning to production, information can be lost, timelines slip, and refinements add up. For a brand doing 50 cases a month, even a 20% refinement rate means 10 extra rounds of production. That cost rarely show